Vaccinex Q3 EPS $(1.09) Up From $(1.65) YoY
Portfolio Pulse from Benzinga Newsdesk
Vaccinex (NASDAQ:VCNX) reported a narrower loss of $(1.09) per share in Q3, improving from a loss of $(1.65) per share in the same quarter last year, marking a 33.94% year-over-year improvement.
November 13, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaccinex reported a 33.94% improvement in its quarterly losses year-over-year, with EPS at $(1.09) compared to $(1.65) from the same period last year.
The improvement in earnings per share (EPS) suggests that Vaccinex is managing to reduce its losses, which could be perceived positively by investors. This may lead to a short-term increase in stock price as the market reacts to the company's better-than-previous financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100